null

null

null

null

null

null

null

null

null

null

null

null

null

null

Minimal long-term debt; primarily equity-financed with ~$200M cash runway; low leverage ratio reduces interest rate sensitivity materially

Low sensitivity; negligible floating-rate debt; higher rates pressure equity valuation and cost of future capital raises for cash-burning biotech

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

AAV vector manufacturing (single-source CDMOs) and zinc finger nuclease reagent suppliers concentrated in US/EU; limited geopolitical chokepoint exposure

Minimal international commercial revenue; partnership milestone payments in USD; sovereign currency devaluation risk is negligible at current stage

Predominantly US-based operations; EU collaborations via Biogen/Sanofi; currency devaluation risk low given USD-denominated milestone/royalty structures

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High dependency on single CDMO partners for gene therapy manufacturing; substitution lead time 12-24 months; exceeds 30% operational input threshold

Cloud disruption risk is moderate; bioinformatics and genomic data pipelines rely on AWS/Azure but core IP and lab operations are on-premise

30-day cloud termination would disrupt R&D data analysis and collaboration tools but would not halt clinical trials or core laboratory functions

Low API coupling risk; proprietary ZFN platform is internally developed; limited third-party API dependencies for core therapeutic discovery engine

Low Howey risk; revenue derives from licensing IP and pharma partnerships, not investor profit-sharing arrangements; standard biotech model

Very High

Moderate GDPR exposure via EU clinical trial patient data; CCPA applies to employee/volunteer data; genomic data handling requires heightened compliance controls

Low antitrust risk; operates in nascent gene editing market without dominant market share; collaborative licensing model reduces exclusionary conduct concern

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

~80-90% transactional/milestone-based from pharma partnerships; ~10-20% recurring via research collaboration fees; highly lumpy revenue recognition

Upfront license fees plus development/regulatory/commercial milestones; future royalties on partnered product sales; no direct commercial product revenue currently

Milestone-based pricing negotiated bilaterally with large pharma; no public price list; pricing power constrained by partner negotiating leverage and competitive gene editing alternatives

Moderate; ZFN platform differentiates but faces CRISPR competition from Editas/Intellia; pricing power improves if clinical data validates superiority

Collaboration gross margins ~60-75% on licensing revenue; R&D-heavy cost structure depresses overall operating margins significantly into negative territory

Free-rider risk low; proprietary ZFN IP is patent-protected; CRISPR commoditization poses longer-term substitution risk rather than free-rider leakage

Revenue growth is sublinear to headcount at partnership scale; scientific staff required for platform maintenance but milestone revenue can scale without proportional hiring

Marginal cost of incremental milestone revenue near zero once partnerships signed; manufacturing scale-up costs are primary variable expense for product advancement

null

At 10x scale, CAC remains low (BD-driven enterprise deals); unit economics improve dramatically with royalty revenue stacking; bottleneck is clinical success rate not sales capacity

No meaningful network effects; platform value derives from proprietary IP and clinical validation, not user-scale dynamics; durability depends on patent moat

-206.7% Return on Assets (Negative equity)

Moderate resilience; large pharma partners maintain R&D budgets through mild recessions but may deprioritize early-stage gene therapy collaborations in severe downturns

Large pharmaceutical and biopharmaceutical companies (Pfizer, Biogen, Sanofi) seeking gene editing platform licenses; high concentration risk with top 3 partners

Academic/government research institutions for early-stage tool licensing; minor revenue contribution; reduces but does not eliminate concentration risk meaningfully

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

0.3% CapEx / Revenue (Low-CapEx Asset-Light)

0001001233

SGMO